Development of 225Ac/213Bi generator based on α-ZrP-PAN composite for targeted alpha therapy

Radioligand therapy using alpha emitters has gained more and more prominence in the last decade. Despite continued efforts to identify new appropriate radionuclides, the combination of 225Ac/213Bi remains among the most promising. Bismuth-213 has been employed in clinical trials in combination with appropriate vectors to treat patients with various forms of cancer, such as leukaemia, bladder cancer, neuroendocrine tumours, melanomas, gliomas, or lymphomas. However, the half-life of 213Bi (T½ = 46 min) implies that its availability for clinical use is limited to hospitals possessing a 225Ac/213Bi radionuclide generator, which is still predominantly scarce. We investigated a new Ac/Bi generator system based on using the composite sorbent α-ZrP-PAN (zirconium(IV) phosphate as active component and polyacrylonitrile as matrix). The developed 225Ac/213Bi generator was subjected to long-term testing after its development. The elution profile was determined and the elution yield, the contamination of the eluate with the parent 225Ac and the contamination of the eluate with the column material were monitored over time.

ONDRAK Lukas;  FIALOVA Katerina;  SAKMAR Michal;  VLK M.;  BRUCHERTSEIFER Frank;  MORGENSTERN Alfred;  KOZEMPEL J.; 

2024-09-05

ELSEVIER SCIENCE INC

JRC138945

1872-9614 (online),   

https://www.sciencedirect.com/science/article/pii/S0969805124000350?via%3Dihub,    https://publications.jrc.ec.europa.eu/repository/handle/JRC138945,   

10.1016/j.nucmedbio.2024.108909 (online),